

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number  
WO 01/15742 A1

(51) International Patent Classification<sup>7</sup>: A61K 49/00, A61M 31/00

(21) International Application Number: PCT/GB00/03310

(22) International Filing Date: 25 August 2000 (25.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9920392.9 27 August 1999 (27.08.1999) GB

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/153,018 (CIP)  
Filed on 9 September 1999 (09.09.1999)

(71) Applicant (for GB only): MARSDEN, John, Christopher [GB/GB]; Frank B Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).


(71) Applicant (for all designated States except US): NY-COMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HENRIKSEN, Ingrid [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). OMTVEIT, Tore [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). KASPARKOVA, Vera [CZ/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). FAHLVIK, Anne, Kjersti [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).

[Continued on next page]

(54) Title: ADMINISTERING A GRAVITY SEGREGATION DISPERSION BY CONTINUOUS INFUSION



(57) Abstract: Method and apparatus for continuous infusion to a subject of dispersions in which the dispersed phase is susceptible to flotation or sedimentation. The dispersion is controllably delivered from an upper or lower extremity of an essentially vertically positioned delivery vessel, e.g. syringe (2), and is then admixed with flushing medium, e.g. from infusion minibag (8), prior to administration to the subject. Vertical positioning of the delivery device maximises the distance through which flotation or sedimentation may occur, thereby substantially reducing the effects of separation over a given period of time compared to use of a corresponding horizontal delivery vessel such as a syringe placed in a conventional syringe driver.

WO 01/15742 A1



(74) **Agents:** MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *With international search report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## ADMINISTERING A GRAVITY SEGREGATION DISPERSION BY CONTINUOUS INFUSION

5

10        This invention relates to the administration of dynamic (i.e. gravity segregating) particulate dispersion systems, e.g. gas-containing diagnostic contrast agents, more particularly to apparatus and a method for the controlled and substantially steady state administration of such dispersions by infusion.

15        In the field of ultrasonography it is well known that contrast agents comprising dispersions of gas microbubbles are particularly efficient backscatterers of ultrasound by virtue of the low density and ease of compressibility of the microbubbles. Such microbubble dispersions, if appropriately stabilised, may permit highly effective ultrasound visualisation of, for example, the vascular system and tissue 20        microvasculature, often at advantageously low doses of the contrast agent.

25        Gas-containing contrast media are also known to be effective in magnetic resonance (MR) imaging, e.g. as susceptibility contrast agents which will act to reduce MR signal intensity. Oxygen-containing contrast media also represent potentially useful paramagnetic MR contrast agents.

30        In the field of X-ray imaging gases such as carbon dioxide may be used as intravascular contrast agents. Moreover, the use of radioactive gases, e.g. radioactive isotopes of inert gases such as xenon, has been proposed in scintigraphy, for example for blood pool imaging.

35        Gas-containing ultrasound contrast agents are usually administered intravenously as a single or multiple bolus dosage, leading to a rapid and pronounced but relatively short lived rise in backscatter intensity in respect of blood-perfused tissue and organs as the

bolus mixes with surrounding blood and is carried through the circulation system. A plot of backscatter intensity against time therefore shows a relatively narrow and high signal intensity peak; backscatter measurements are normally made during the existence of this peak, although this may give rise to problems in, for example, the imaging of deeper tissue and organs where high backscatter from overlying tissue may cause excessive shadowing during the peak period.

As discussed in WO-A-9748337, diagnostic artefacts such as shadowing may be reduced by controlling the rate of administration of the contrast agent and/or by administering a flush such as normal saline after administration of the contrast agent. Contrast agent administration rates of  $1-8 \times 10^6$  vesicles/kg-sec or  $1 \times 10^{-7}$  to  $3 \times 10^{-3}$  cc gas/kg-sec and flush rates of 0.01-2.4 ml/sec are suggested; the contrast agent is typically administered over a period of 5-20 seconds, and any subsequent flush is typically administered over a period in the range 10 seconds to 10 minutes.

Continuous infusion of ultrasound contrast agents, for example over a period in the range from one minute to one hour, is of potential interest in that it may permit administration of the contrast agent at a rate which minimises diagnostic artefacts such as shadowing and may lengthen the useful time window for imaging beyond the relatively short duration of the backscatter signal peak resulting from passage of a contrast agent bolus.

Thus, for example, Albrecht et al. in Radiology 207, pp. 339-347 (1998) note that the use of continuous contrast agent infusion to provide prolonged enhancement of Doppler signals is advantageous in that it may permit completion of lengthy imaging procedures such as studies of the renal arteries or peripheral leg veins and may optimise dose effectiveness of the contrast agents, as well as reducing saturation artefacts.

- 3 -

Administration of contrast agents by infusion may also be useful in procedures based on imaging of contrast agent in the recirculating phase following admixture with the blood pool, as described in WO-A-5 9908714.

A problem with the continuous infusion of gas-containing diagnostic contrast agents arises from the 10 tendency of gas-containing components such as microbubbles to float, since this will lead to inhomogeneities forming within vessels such as power-driven syringes which may be used to administer the contrast agent. This may, for example, lead to an 15 increase in microbubble concentration in the upper part of such a vessel and/or to changes in size distribution occurring at various points within the vessel as larger microbubbles float more rapidly than smaller microbubbles.

A possible solution to this problem is proposed in WO-A-9927981, which discloses powered injector systems 20 comprising a syringe which is subjected to rotational or rocking motion in order to maintain homogeneity within the contents thereof. In specific embodiments the barrel of the syringe is positioned horizontally in contact with wheels or moveable brackets which are 25 capable of alternately rotating the syringe in opposite directions about its longitudinal (i.e. horizontal) axis.

It will be appreciated that the incorporation of such rotational or other agitational means into syringe 30 driver apparatus necessarily complicates the design and significantly increases the cost of such apparatus, so that there is an ongoing need for apparatus which permits the continuous infusion of gas-containing 35 ultrasound contrast agents or other gravity segregating dispersions while maintaining substantial homogeneity of the contrast agent or other dispersion.

The present invention is based on the finding that

- 4 -

controlled delivery of a substantially homogeneous gravity segregating dispersion may be achieved by an infusion procedure in which the dispersion is delivered from an upper or lower extremity of an essentially vertically positioned delivery vessel, e.g. a syringe, tubing or other cylindrically shaped reservoir, and is admixed with a flushing medium prior to administration to a subject.

By using an essentially vertically positioned cylindrical delivery vessel such as a syringe, as opposed to the horizontal orientation normally employed in delivery devices such as syringe drivers, the height of the dispersion sample in the vessel is greatly increased, thereby extending the distance through which gravity segregation may occur. Since relatively low density dispersed moieties such as microbubbles or other gas-containing components of a given size will rise through carrier liquid at a constant rate, this significantly reduces the effects of flotation separation and thereby improves dose control over a given period of time. Similar considerations apply to dispersions of relatively high density microparticles, emulsion droplets etc. which tend to sediment over time.

Co-administration of the dispersion with an admixed flushing medium further enhances product homogeneity, e.g. by reducing the residence time of the dispersion in connecting tubing etc., thereby reducing its susceptibility to gravity segregation. Admixture with flushing medium also permits particularly efficient control of administration of the dispersion since the flow rates of both the dispersion and the flushing medium may be independently controlled.

Admixture of the dispersion with flushing medium almost immediately prior to administration to a subject is particularly advantageous in the administration of dispersions such as gas microbubble-containing contrast agents, which often show instability if stored in

diluted form, e.g. if diluted prior to transfer into a syringe or other delivery vessel.

Moreover, where administration is by intravascular (e.g. intravenous) injection, coadministration of 5 admixed flushing medium at a single injection site assists in maintenance of an open injection route independent of dispersion flow and local blood flow variations.

Thus according to one aspect of the present 10 invention there is provided a method of administering a gravity segregating dispersion, e.g. a gas-containing contrast agent, to a subject by continuous infusion, wherein said dispersion is controllably delivered from an upper or lower extremity of an essentially vertically 15 positioned delivery vessel, e.g. a syringe, and thereafter is admixed with a flushing medium prior to administration to the subject.

According to a further aspect the invention provides apparatus useful in the administration of a 20 gravity segregating dispersion, e.g. a gas-containing contrast agent, by continuous infusion, said apparatus comprising (i) a delivery device adapted to retain a dispersion-containing delivery vessel in an essentially vertical position and controllably to expel dispersion 25 from an upper or lower extremity of said vessel; (ii) mixing means adapted to effect admixture of said expelled dispersion with a flushing medium; and (iii) conduit means adapted to conduct said admixed dispersion and flushing medium to an administration device.

30 The term "essentially vertical" as used herein denotes that the longitudinal axis of the delivery vessel should be positioned within about 30° of vertical, preferably within 15° and more preferably within 5° of vertical. The vessel may be positioned for 35 delivery of dispersion from either its upper or lower extremity, i.e. for upward or downward delivery respectively.

- 6 -

In the case of dispersions comprising a relatively low density dispersed phase, such flotation as may occur during administration of the dispersion will tend to lead to a reduction in dispersed phase concentration as 5 administration proceeds in the case where the delivery vessel is positioned for upward delivery and to a corresponding increase in concentration in the case where the delivery vessel is positioned for downward delivery. It will be appreciated that the converse will 10 apply for dispersions comprising a relatively high density dispersed phase which is susceptible to sedimentation. Such concentration changes may, if desired, be counteracted by appropriate adjustment of the rates at which the dispersion and flushing medium 15 are coadministered. Additionally or alternatively the delivery vessel may be inverted at a suitable stage during infusion.

It is preferred that the delivery vessel is positioned so that the bulk flow direction of dispersion 20 during expulsion is the same as the direction of segregation of the dispersed phase, since this will assist in counteracting the formation of concentration gradients of dispersed phase within the dispersion during administration. Thus, for example, in the case 25 of dispersions such as gas-containing contrast agents in which the dispersed phase is susceptible to flotation, it is preferred to use delivery vessels positioned for upward delivery.

Delivery devices which may be used in apparatus 30 according to the invention include syringe driver means such as power injection systems in which the syringe plunger is controllably driven by an appropriate automated mechanism, for example an electrically powered and controlled helical screw or push rod.

35 Where the infused dispersion is a gas-containing contrast agent it may, for example, be administered at a rate in the range 0.001-0.5 ml/minute, preferably 0.01-

- 7 -

0.25 ml/minute, and may be selected to take account of factors such as the gas concentration and, in the case of ultrasound studies, the desired degree of attenuation. The infusion rate will depend on the body 5 weight of the subject, and will typically be about 0.06  $\mu$ l/kg/hour. Such contrast agents may, for example, be administered over an infusion period of up to one hour, typically for a period of 15-20 minutes; steady state distribution of contrast agent *in vivo* will typically be 10 achieved after 1-2 minutes

The flushing medium may be any appropriate biocompatible liquid, but is preferably normal (i.e. 0.9%) saline. It may, for example, be administered by gravitational flow using appropriate flow rate 15 controlling means, or may be delivered using a controllable pump. Flow rates of 0.5-2 ml/minute, have been found to be appropriate although higher flow rates, e.g. up to 5 ml/minute, may also be useful.

Mixing of the dispersion and flushing medium may, 20 for example, be effected in a three way connector, e.g. a T-piece, a Y-piece or a tap such as a three way stopcock, which is also connected via appropriate tubing to an administration device, e.g. an injection device such as a needle or catheter. It is preferred that 25 connections are kept to a minimum and are made using low volume tubing in order to minimise transit time of the dispersion and thus to minimise the potential for segregation of the dispersed phase.

Gases which may be present in gas-containing 30 contrast agents administered in accordance with the invention include any biocompatible substances, including mixtures, which are at least partially, e.g. substantially or completely, in gaseous or vapour form at the normal human body temperature of 37°C. 35 Representative gases thus include air; nitrogen; oxygen; carbon dioxide; hydrogen; inert gases such as helium, argon, xenon or krypton; sulphur fluorides such as

sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; optionally halogenated silanes such as methylsilane or dimethylsilane; low molecular weight hydrocarbons (e.g. containing up to 7 carbon atoms), for example alkanes such as methane, ethane, a propane, a butane or a pentane, cycloalkanes such as cyclopropane, cyclobutane or cyclopentane, alkenes such as ethylene, propene, propadiene or a butene, and alkynes such as acetylene or propyne; ethers such as dimethyl ether; ketones; esters; halogenated low molecular weight hydrocarbons (e.g. containing up to 7 carbon atoms); and mixtures of any of the foregoing. Advantageously at least some of the halogen atoms in halogenated gases are fluorine atoms; thus biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethane, bromotrifluoromethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane, chlorotrifluoroethylene, fluoroethylene, ethylfluoride, 1,1-difluoroethane and perfluorocarbons. Representative perfluorocarbons include perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoro-iso-butane), perfluoropentanes, perfluorohexanes or perfluoroheptanes; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g. perfluorobut-2-ene), perfluorobutadiene, perfluoropentenes (e.g. perfluoropent-1-ene) or perfluoro-4-methylpent-2-ene; perfluoroalkynes such as perfluorobut-2-yne; and perfluorocycloalkanes such as perfluorocyclobutane, perfluoromethylcyclobutane, perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentanes,

perfluorocyclohexane, perfluoromethylcyclohexane or perfluorocycloheptane. Other halogenated gases include methyl chloride, fluorinated (e.g. perfluorinated) ketones such as perfluoroacetone and fluorinated (e.g. perfluorinated) ethers such as perfluorodiethyl ether.

5 The use of perfluorinated gases, for example sulphur hexafluoride and perfluorocarbons such as perfluoropropane, perfluorobutanes, perfluoropentanes and perfluorohexanes, may be particularly advantageous

10 in view of the recognised high stability in the blood stream of microbubbles containing such gases. Other gases with physicochemical characteristics which cause them to form highly stable microbubbles in the blood stream may likewise be useful.

15 Representative examples of contrast agent formulations include microbubbles of gas stabilised (e.g. at least partially encapsulated) by a coalescence-resistant surface membrane (for example gelatin, e.g. as described in WO-A-8002365), a filmogenic protein (for

20 example an albumin such as human serum albumin, e.g. as described in US-A-4718433, US-A-4774958, US-A-4844882, EP-A-0359246, WO-A-9112823, WO-A-9205806, WO-A-9217213, WO-A-9406477, WO-A-9501187 or WO-A-9638180), a polymer material (for example a synthetic biodegradable polymer

25 as described in EP-A-0398935, an elastic interfacial synthetic polymer membrane as described in EP-A-0458745, a microparticulate biodegradable polyaldehyde as described in EP-A-0441468, a microparticulate N-dicarboxylic acid derivative of a polyamino acid -

30 polycyclic imide as described in EP-A-0458079, or a biodegradable polymer as described in WO-A-9317718 or WO-A-9607434), a non-polymeric and non-polymerisable wall-forming material (for example as described in WO-A-9521631), or a surfactant (for example a

35 polyoxyethylene-polyoxypropylene block copolymer surfactant such as a Pluronic, a polymer surfactant as described in WO-A-9506518, or a film-forming surfactant

- 10 -

such as a phospholipid, e.g. as described in WO-A-9211873, WO-A-9217212, WO-A-9222247, WO-A-9409829, WO-A-9428780, WO-A-9503835 or WO-A-9729783). Contrast agent formulations comprising free microbubbles of selected gases, e.g. as described in WO-A-9305819, or comprising a liquid-in-liquid emulsion in which the boiling point of the dispersed phase is below the body temperature of the subject to be imaged, e.g. as described in WO-A-9416739, may also be used.

Other useful gas-containing contrast agent formulations include gas-containing solid systems, for example microparticles (especially aggregates of microparticles) having gas contained therewithin or otherwise associated therewith (for example being adsorbed on the surface thereof and/or contained within voids, cavities or pores therein, e.g. as described in EP-A-0122624, EP-A-0123235, EP-A-0365467, WO-A-9221382, WO-A-9300930, WO-A-9313802, WO-A-9313808 or WO-A-9313809). It will be appreciated that the echogenicity of such microparticulate contrast agents may derive directly from the contained/associated gas and/or from gas (e.g. microbubbles) liberated from the solid material (e.g. upon dissolution of the microparticulate structure). The invention may also be useful in conjunction with contrast agent systems based on microspheres comprising a therapeutic compound as described in e.g. WO-A-9851284 and WO-A-9927981.

The disclosures of all of the above-described documents relating to gas-containing contrast agent formulations are incorporated herein by reference.

Gas microbubbles and other gas-containing materials such as microparticles preferably have an initial average size not exceeding 10  $\mu\text{m}$  (e.g. of 7  $\mu\text{m}$  or less) in order to permit their free passage through the pulmonary system following administration, e.g. by intravenous injection. However, larger microbubbles may be employed where, for example, these contain a mixture

- 11 -

of one or more relatively blood-soluble or otherwise diffusible gases such as air, oxygen, nitrogen or carbon dioxide with one or more substantially insoluble and non-diffusible gases such as perfluorocarbons. Outward diffusion of the soluble/diffusible gas content following administration will cause such microbubbles rapidly to shrink to a size which will be determined by the amount of insoluble/non-diffusible gas present and which may be selected to permit passage of the resulting microbubbles through the lung capillaries of the pulmonary system.

Where phospholipid-containing contrast agent formulations are employed in accordance with the invention, e.g. in the form of phospholipid-stabilised gas microbubbles, representative examples of useful phospholipids include lecithins (i.e. phosphatidylcholines), for example natural lecithins such as egg yolk lecithin or soya bean lecithin, semisynthetic (e.g. partially or fully hydrogenated) lecithins and synthetic lecithins such as dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine; phosphatidic acids; phosphatidylethanolamines; phosphatidylserines; phosphatidylglycerols; phosphatidylinositols; cardiolipins; sphingomyelins; fluorinated analogues of any of the foregoing; mixtures of any of the foregoing and mixtures with other lipids such as cholesterol. The use of phospholipids predominantly (e.g. at least 75%) comprising molecules individually bearing net overall charge, e.g. negative charge, for example as in naturally occurring (e.g. soya bean or egg yolk derived), semisynthetic (e.g. partially or fully hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and/or cardiolipins, for example as described in WO-A-9729783, may be particularly

advantageous.

Representative examples of materials useful in gas-containing contrast agent microparticles include carbohydrates (for example hexoses such as glucose, fructose or galactose; disaccharides such as sucrose, lactose or maltose; pentoses such as arabinose, xylose or ribose;  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrins; polysaccharides such as starch, hydroxyethyl starch, amylose, amylopectin, glycogen, inulin, pulullan, dextran, carboxymethyl dextran, dextran phosphate, ketodextran, 10 aminoethyl dextran, alginates, chitin, chitosan, hyaluronic acid or heparin; and sugar alcohols, including alditols such as mannitol or sorbitol), inorganic salts (e.g. sodium chloride), organic salts (e.g. sodium citrate, sodium acetate or sodium tartrate), X-ray contrast agents (e.g. any of the commercially available carboxylic acid and non-ionic amide contrast agents typically containing at least one 2,4,6-triiodophenyl group having substituents such as 20 carboxyl, carbamoyl, N-alkylcarbamoyl, N-hydroxyalkylcarbamoyl, acylamino, N-alkylacylamino or acylaminomethyl at the 3- and/or 5-positions, as in metrizoic acid, diatrizoic acid, iothalamic acid, ioxaglic acid, iohexol, iopentol, iopamidol, iodixanol, 25 iopromide, metrizamide, iodipamide, meglumine iodipamide, meglumine acetrizoate and meglumine diatrizoate), polypeptides and proteins (e.g. gelatin or albumin such as human serum albumin), and mixtures of any of the foregoing.

30 The method and apparatus of the invention may be particularly useful for infusion of the ultrasound contrast agents known as Levovist, Albunex, Optison, Definity, Imagent, Sonovue, Echogen, Sonogen and Sonazoid.

35 The method and apparatus of the invention may also be useful in sequential imaging procedures, for example in which a patient undergoes a first period of contrast

agent infusion and imaging, is then subjected to stress (e.g. through exercise or by administration of a pharmacological stress agent such as adenosine, dobutamine, dipyridamole or arbutamine) and undergoes a 5 second period of contrast agent infusion and imaging during or after this subjection to stress.

Brief description of drawings

10 In the accompanying drawings:

Fig. 1 is a schematic representation of one embodiment of apparatus useful in accordance with the invention;

15 Fig. 2 comprises plots of microbubble concentration against infusion time for the *in vitro* test system described in Example 6 hereinafter and for a comparative study using a horizontally positioned syringe; and

20 Fig. 3 comprises plots of echogenicity against time obtained in accordance with the *in vivo* studies described in Example 15 hereinafter.

Referring to Fig. 1 in more detail, syringe driver 1 (detail not shown) is adapted to receive vertically positioned syringe 2 and controllably to drive syringe plunger 3 in an upward direction so as to expel 25 dispersion 4 through delivery outlet 5 at the upper extremity of the syringe. Three way stopcock 6 connects outlet 5 and feed 7 from saline infusion minibag 8 to conduit tube 9 which is connected via Luer lock 10 to infusion feed line 11, which in turn is connectable to 30 an injection needle or catheter (not shown). The flow rate of dispersion is controllable by adjusting syringe driver 1. The flow rate of saline from minibag 8 is controllable by adjusting one or more of stopcock 6, valve 12 and the height of the minibag.

35 The following non-limitative examples serve to illustrate the invention.

Preparation 1 - Hydrogenated phosphatidylserine-  
encapsulated perfluorobutane microbubbles

Hydrogenated phosphatidylserine (5 mg/ml in a 1% w/w  
5 solution of propylene glycol in purified water) and  
perfluorobutane gas were homogenised in-line at 7800 rpm  
and ca. 40°C to yield a creamy-white microbubble  
dispersion. The dispersion was fractionated to  
substantially remove undersized microbubbles (<2 µm) and  
10 the volume of the dispersion was adjusted to the desired  
microbubble concentration. Sucrose was then added to a  
concentration of 92 mg/ml. 2 ml portions of the  
resulting dispersion were filled into 10 ml flat-  
bottomed vials specially designed for lyophilisation,  
15 and the contents were lyophilised to give a white porous  
cake. The lyophilisation chamber was then filled with  
perfluorobutane and the vials were sealed. Unless  
otherwise stated, 2 ml of water were added to a  
lyophilised product-containing vial prior to use and the  
20 contents were hand-shaken for several seconds, giving a  
perfluorobutane microbubble dispersion with a  
concentration range of 5-20 x 10<sup>8</sup> microbubbles/ml (7-13  
µl/ml).

25 Examples 1-6 - In vitro studies

The contents of vials prepared as in Preparation 1 were  
mixed with water (5 ml) from a syringe and gently hand  
shaken to give perfluorobutane microbubble dispersions  
30 with a microbubble concentration of about 3 µl/ml  
(Examples 1 to 5). In the procedure of Example 6 the  
contents of three vials were each mixed with 2 ml of  
water and the resulting dispersions were then pooled.  
Each of the thus-obtained microbubble dispersions was  
35 drawn into a syringe, which was vertically positioned in  
a module DPC syringe pump and connected to a low volume  
extension tube equipped with a 3 way stopcock and an

- 15 -

administration set for delivery of normal saline from an infusion minibag, as shown in Fig.1. The syringe pump rate and the saline rate were varied as shown in Table 1, which also records the calculated and observed 5 microbubble concentrations and the observed periods over which steady state infusion was maintained (measured as timings from the start of infusion).

Table 1

10

15

20

25

30

35

Example No.	Syringe pump rate (ml/min)	Saline flow rate (ml/min)	Calculated microbubble conc. ( $\mu$ l/ml)	Observed microbubble conc. ( $\mu$ l/ml)	Period of steady state infusion (min)
1	0.017	1	0.05	0.11±0.04	10-60
2	0.1	1	0.3	0.29±0.05	5-30
3	0.2	1	0.6	0.57±0.06	5-16
4	0.017	2	0.025	0.08±0.01	10-60
5	0.1	2	0.15	0.17±0.03	5-30
6	0.1	2	0.35	0.44±0.04	5-35

Fig. 2 shows a plot of microbubble concentration (expressed as percentage of initial concentration) against time as determined in the procedure of Example 6. For comparison, the variation of microbubble concentration with time determined using an equivalent procedure with a horizontally positioned syringe is also shown. It can readily be seen that in the procedure according to the invention a substantially steady microbubble concentration is maintained, whereas in the comparative test the microbubble concentration rapidly decreases as infusion proceeds.

It will be appreciated that the length of the administration window will be shortened at higher syringe pump rates given the fixed volume of contrast

- 16 -

agent present in a syringe.

Examples 7-14 - In vitro studies

5 In order to demonstrate the possibility of adjusting microbubble dose for different infusion procedures, a study was conducted according to the general procedure of Example 6 above, using a saline infusion rate of 2 ml/minute while varying the syringe pump rate as shown  
 10 in Table 2, which also records the calculated and observed microbubble concentrations.

Table 2

15	Example No.	Infusion time (min)	Syringe pump rate (ml/min)	Calculated microbubble conc. ( $\mu$ l/ml)	Observed microbubble conc. ( $\mu$ l/ml)
16	7	5	0.1	0.15	0.20
17	8	10	0.05	0.075	0.10
18	9	15	0.05	0.075	0.12
19	10	20	0.12	0.18	0.20
20	11	25	0.12	0.18	0.19
21	12	30	0.05	0.075	0.08
22	13	35	0.05	0.075	0.09
23	14	40	0.05	0.075	0.07

25

Example 15 - In vivo study

Second harmonic imaging of the anterior myocardium was performed on an open chest model in 6 dogs (15-25kg, both sexes) using an ATL HDI 3000 scanner with a mechanical index of 0.6 and 1:4 triggering. Images were recorded following injection of a bolus of contrast agent prepared as in Preparation 1 at a concentration of 30 nl perfluorobutane/kg, and during infusion of

- 17 -

contrast agent in accordance with the method of the invention at rates corresponding to 5, 15, 45 and 135 nl perfluorobutane/kg/min. The contrast effects in the region of interest are shown in Fig. 3.

5

Example 16

10 A microbubble suspension is prepared as in Example 1 of WO-A-9748337 and administered according to the method of the invention.

Example 17

15 The commercially available ultrasound product sold under the trade name Optison is administered according to the method of the invention.

Example 18

20 Contrast agents are prepared as in Example 2 of WO-A-9927981 and administered according to the method of the invention.

Example 19

25 Triggered ultraharmonic cardiac imaging of a patient with normal cardiac arteries was performed with triggering at every heart beat, every second heart beat, every fourth heart beat and every eighth heart beat.

30 The heart was imaged from apical 2-chamber and 4-chamber views during dipyridamole-induced stress. Contrast agent prepared as in Preparation 1 was infused at a rate of 10  $\mu$ l/kg/minute throughout the entire imaging period.

35 Increased videodensity was observed in each of the myocardial segments (the myocardium was divided into 16 segments according to the definitions of the American

- 18 -

Society of Echocardiography) for each of the triggering intervals. The increase in intensity ranged from 8 to 10 dB in the different myocardial segments for the highest triggering interval (8 heart beats).

Claims

1. A method of administering a gravity segregating dispersion to a subject by continuous infusion, wherein  
5 said dispersion is controllably delivered from an upper or lower extremity of an essentially vertically positioned delivery vessel and thereafter is admixed with a flushing medium prior to administration to the subject.
- 10 2. A method as claimed in claim 1 wherein said delivery vessel comprises a syringe.
- 15 3. A method as claimed in claim 2 wherein delivery of said dispersion from said syringe is controlled by a syringe driver.
- 20 4. A method as claimed in any of the preceding claims wherein said dispersion is a gas-containing contrast agent.
- 25 5. A method as claimed in claim 4 wherein said gas comprises sulphur hexafluoride or a perfluorinated low molecular weight hydrocarbon.
6. A method as claimed in claim 5 wherein said perfluorinated hydrocarbon is perfluoropropane or perfluorobutane.
- 30 7. A method as claimed in any of claims 4 to 6 wherein said gas is present as albumin-stabilised microbubbles.
- 35 8. A method as claimed in any of claims 4 to 6 wherein said gas is present as phospholipid-stabilised microbubbles.

- 20 -

9. A method as claimed in claim 8 wherein said phospholipid predominantly comprises phosphatidylserine.

10. A method as claimed in any of claims 4 to 9  
5 wherein the delivery vessel comprises a syringe positioned for upward delivery of said contrast agent.

11. A method as claimed in any of the preceding claims wherein said flushing medium is normal saline.

10

12. A method as claimed in any of the preceding claims wherein the admixed dispersion and flushing medium are administered by injection.

15 13. Apparatus for use in administration of a gravity segregating dispersion by continuous infusion, said apparatus comprising:

20 (i) a delivery device adapted to receive a dispersion-containing delivery vessel in an essentially vertical position and controllably to expel dispersion from an upper or lower extremity of said vessel;

(ii) mixing means adapted to effect admixture of said expelled dispersion with a flushing medium; and

25 (iii) conduit means adapted to conduct said admixed dispersion and flushing medium to an administration device.

14. Apparatus as claimed in claim 13 wherein said delivery device is a syringe driver adapted to receive an essentially vertically positioned syringe.

30 15. Apparatus as claimed in claim 13 or claim 14 wherein said mixing means comprise a three way connector or tap adapted to connect said delivery vessel and a source of flushing medium to said conduit means.

35 16. Apparatus as claimed in any of claims 13 to 15

- 21 -

which further comprises flow rate controlling means for controlling the rate of flow of said flushing medium.

17. Apparatus as claimed in any of claims 13 to 16  
5 which further comprises means for inverting the position of said delivery vessel.

18. Use of apparatus as claimed in any of claims 13 to 17 in administration of a gravity segregating  
10 dispersion to a subject by continuous infusion.




FIG. 1

2 / 3




FIG. 2

3 / 3




FIG. 3

## INTERNATIONAL SEARCH REPORT

Internat' Application No  
PCT/GB 00/03310A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K49/00 A61M31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 48337 A (IMARX PHARMACEUTICAL CORP) 24 December 1997 (1997-12-24) cited in the application abstract page 69, line 8 -page 76, line 2; figures 1,2 ---	1-18
Y	US 5 897 851 A (QUAY STEVEN C ET AL) 27 April 1999 (1999-04-27) the whole document ---	1-18
A	WO 99 32034 A (MARDSEN JOHN CHRISTOPHER ;ERIKSEN MORTEN (NO); FRIGSTAD SIGMUND (N) 1 July 1999 (1999-07-01) page 9, line 29 -page 14, line 32 ---	1-18 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 October 2000

Date of mailing of the international search report

10/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentdaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Nielsen, M

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/GB 00/03310

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 18501 A (MARSDEN JOHN CHRISTOPHER ; HELLEBUST HALLDIS (NO); HOFF LARS (NO);) 7 May 1998 (1998-05-07) page 1, line 1 -page 11, line 22 ---	1-18
A	US 4 572 203 A (FEINSTEIN STEVEN B) 25 February 1986 (1986-02-25) abstract; figure 1 -----	1,13

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internat' Application No  
PCT/GB 00/03310

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9748337	A 24-12-1997	US 6033645 A		07-03-2000
		AU 3313197 A		07-01-1998
		EP 0930844 A		28-07-1999
US 5897851	A 27-04-1999	AU 6327796 A		30-12-1996
		EP 0871499 A		21-10-1998
		JP 11506960 T		22-06-1999
		WO 9640282 A		19-12-1996
WO 9932034	A 01-07-1999	AU 1677199 A		12-07-1999
		NO 20003164 A		15-08-2000
WO 9818501	A 07-05-1998	AU 4786697 A		22-05-1998
		AU 4786897 A		22-05-1998
		AU 4786997 A		22-05-1998
		BG 103438 A		31-01-2000
		BR 9712683 A		19-10-1999
		CN 1234742 A		10-11-1999
		CZ 9901494 A		15-09-1999
		EP 0973552 A		26-01-2000
		EP 0971747 A		19-01-2000
		EP 0946202 A		06-10-1999
		WO 9818496 A		07-05-1998
		WO 9818497 A		07-05-1998
		NO 991889 A		28-06-1999
		US 6051207 A		18-04-2000
		AU 4786797 A		22-05-1998
		AU 4787097 A		22-05-1998
		EP 0991427 A		12-04-2000
		EP 0963209 A		15-12-1999
		WO 9818495 A		07-05-1998
		WO 9818498 A		07-05-1998
		AU 4718297 A		22-05-1998
		BG 103439 A		31-01-2000
		BR 9713978 A		02-05-2000
		CN 1238700 A		15-12-1999
		EP 1007101 A		14-06-2000
		WO 9818500 A		07-05-1998
		NO 991890 A		28-06-1999
		AU 7068798 A		13-11-1998
		EP 0977600 A		09-02-2000
		WO 9847541 A		29-10-1998
		HU 9904595 A		28-04-2000
US 4572203	A 25-02-1986	AT 397034 B		25-01-1994
		AT 900484 A		15-06-1993
		AU 571863 B		28-04-1988
		AU 2576984 A		15-08-1984
		BR 8404941 A		26-12-1984
		CA 1221759 A		12-05-1987
		DE 3490013 C		15-03-1990
		DE 3490013 T		21-02-1985
		EP 0135563 A		03-04-1985
		FR 2541108 A		24-08-1984
		GB 2143327 A,B		06-02-1985
		IL 70784 A		31-12-1987
		JP 2024139 B		28-05-1990
		JP 60500486 T		11-04-1985

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No  
PCT/GB 00/03310

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4572203	A	NL 8420041 A,B,	03-12-1984
		SE 466634 B	16-03-1992
		SE 8404797 A	25-09-1984
		WO 8402838 A	02-08-1984
		US 4718433 A	12-01-1988